文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

Shwachman-Diamond综合征合并MDS或AML的临床特征与结局:多中心回顾性队列研究

Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Haematol · 2019-12-23

3年总生存率MDS为51%,白血病为11%。监测与治疗差异大,提示预后差,需改进监测与风险分层。

要点

  • Shwachman-Diamond综合征合并MDS/AML预后差,AML患者中位生存不足1年。
  • 多数患者在诊断髓系恶性肿瘤前已知晓Shwachman-Diamond综合征,但骨髓监测比例低。
  • 接受监测的患者3年总生存率62%,未监测者28%,差异无统计学意义。

核心结论

  • Shwachman-Diamond综合征合并MDS或AML预后差,源于治疗耐药和治疗相关毒性。

研究设计与样本

  • 多中心回顾性队列研究,与北美Shwachman-Diamond综合征注册中心合作,回顾2001年3月1日至2017年10月5日美加17个中心病历,最终纳入36例患者。

主要发现

  • 36例患者中10例(28%)初诊为AML,26例(72%)初诊为MDS。
  • 3年总生存率:白血病患者11%(95% CI 1-39),MDS患者51%(95% CI 29-68)。
  • 26例MDS患者中18例(69%)接受 upfront 治疗(14例造血干细胞移植,4例化疗),4例(15%)未治疗,2例(8%)进展为AML。

临床怎么用

  • 对Shwachman-Diamond综合征患者应考虑骨髓监测以早期发现MDS/AML,但需进一步研究优化监测方案。
  • 治疗需权衡耐药疾病与治疗相关毒性,异基因造血干细胞移植是重要选择。

局限性

  • 回顾性研究,样本量小(36例),监测与治疗异质性大。
  • 部分患者缺乏中央病理复核样本,监测获益分析未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data to inform surveillance and treatment for leukaemia predisposition syndromes are scarce and recommendations are largely based on expert opinion. This study aimed to investigate the clinical features and outcomes of patients with myelodysplastic syndrome or acute myeloid leukaemia and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developing myeloid malignancies. METHODS: We did a multicentre, retrospective, cohort study in collaboration with the North American Shwachman-Diamond Syndrome Registry. We reviewed patient medical records from 17 centres in the USA and Canada. Patients with a genetic (biallelic mutations in the SBDS gene) or clinical diagnosis (cytopenias and pancreatic dysfunction) of Shwachman-Diamond syndrome who developed myelodysplastic syndrome or acute myeloid leukaemia were eligible without additional restriction. Medical records were reviewed between March 1, 2001, and Oct 5, 2017. Masked central review of bone marrow pathology was done if available to confirm leukaemia or myelodysplastic syndrome diagnosis. We describe the clinical features and overall survival of these patients. FINDINGS: We initially identified 37 patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia. 27 patients had samples available for central pathology review and were reclassified accordingly (central diagnosis concurred with local in 15 [56%] cases), 10 had no samples available and were classified based on the local review data, and 1 patient was excluded at this stage as not eligible. 36 patients were included in the analysis, of whom 10 (28%) initially presented with acute myeloid leukaemia and 26 (72%) initially presented with myelodysplastic syndrome. With a median follow-up of 4·9 years (IQR 3·9-8·4), median overall survival for patients with myelodysplastic syndrome was 7·7 years (95% CI 0·8-not reached) and 0·99 years (95% CI 0·2-2·4) for patients with acute myeloid leukaemia. Overall survival at 3 years was 11% (95% CI 1-39) for patients with leukaemia and 51% (29-68) for patients with myelodysplastic syndrome. Management and surveillance were variable. 18 (69%) of 26 patients with myelodysplastic syndrome received upfront therapy (14 haematopoietic stem cell transplantation and 4 chemotherapy), 4 (15%) patients received no treatment, 2 (8%) had unavailable data, and 2 (8%) progressed to acute myeloid leukaemia before receiving treatment. 12 patients received treatment for acute myeloid leukaemia-including the two patients initially diagnosed with myelodysplastic who progressed- two (16%) received HSCT as initial therapy and ten (83%) received chemotherapy with intent to proceed with HSCT. 33 (92%) of 36 patients (eight of ten with leukaemia and 25 of 26 with myelodysplastic syndrome) were known to have Shwachman-Diamond syndrome before development of a myeloid malignancy and could have been monitored with bone marrow surveillance. Bone marrow surveillance before myeloid malignancy diagnosis was done in three (33%) of nine patients with leukaemia for whom surveillance status was confirmed and 11 (46%) of 24 patients with myelodysplastic syndrome. Patients monitored had a 3-year overall survival of 62% (95% CI 32-82; n=14) compared with 28% (95% CI 10-50; n=19; p=0·13) without surveillance. Six (40%) of 15 patients with available longitudinal data developed myelodysplastic syndrome in the setting of stable blood counts. INTERPRETATION: Our results suggest that prognosis is poor for patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia owing to both therapy-resistant disease and treatment-related toxicities. Improved surveillance algorithms and risk stratification tools, studies of clonal evolution, and prospective trials are needed to inform effective prevention and treatment strategies for leukaemia predisposition in patients with Shwachman-Diamond syndrome. FUNDING: National Institute of Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Myers KC, Furutani E, Weller E, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2019. PMID: 31879230. doi:10.1016/S2352-3026(19)30206-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。